Skip to main content
Premium Trial:

Request an Annual Quote

Denator, Dutch Medical Centers Developing Cancer Biomarker Dx Platform

NEW YORK (GenomeWeb News) – Denator and two Dutch medical centers today announced a collaboration to develop a biomarker discovery platform for the diagnosis of cancer.

Denator, based in Gothenburg, Sweden, is working with Erasmus Medical Center and Amsterdam Medical Center to develop and verify a prototype platform for monitoring specific protein and peptide degradation patterns in biological fluids and tissue sections. Denator is applying its heat stabilization technology to the project, which is being funded by the EU Eurostars program.

Degradation patterns are specific for different tissue types and specific diseases, the partners said, and the platform being developed could result in the discovery of new disease biomarkers that in turn enable early diagnosis of cancer.

"To utilize specific degradation patterns correlating to specific cancer types could provide the research community with an important tool to help advance the understanding of the complexity of cancer and eventual early diagnosis," Theo Luider, head of the department of neurology at Erasmus Medical Center, said in a statement. "This project holds the potential of immensely facilitating the diagnostic process."

The Scan

Missed Early Cases

A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports.

Limited Journal Editor Diversity

A survey finds low diversity among scientific and medical journal editors, according to The Scientist.

How Much of a Threat?

Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned.

PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs

In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.